Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Among gynaecological cancers, epithelial ovarian cancers are the most deadly cancers while endometrial cancers are the most common diseases. Efforts to establish relevant novel diagnostic, screening and prognostic markers are aimed to help reduce the high level of mortality, chemoresistance and recurrence, particularly in ovarian cancer. MicroRNAs, the class of post-transcriptional regulators, have emerged as the promising diagnostic and prognostic markers associated with various diseased states recently. Urine has been shown as the source of microRNAs several years ago; however, there has been lack of information on urine microRNA expression in ovarian and endometrial cancers till now. In this pilot study, we examined the expression of candidate cell-free urine microRNAs in ovarian cancer and endometrial cancer patients using quantitative real-time PCR. We compared the expression between pre- and post-surgery ovarian cancer samples, and between patients with ovarian and endometrial cancers and healthy controls, within three types of experiments. These experiments evaluated three different isolation methods of urine RNA, representing two supernatant and one exosome fractions of extracellular microRNA. In ovarian cancer, we found miR-92a significantly up-regulated, and miR-106b significantly down-regulated in comparison with control samples. In endometrial cancer, only miR-106b was found down-regulated significantly compared to control samples. Using exosome RNA, no significant de-regulations in microRNAs expression could be found in either of the cancers investigated. We propose that more research should now focus on confirming the diagnostic potential of urine microRNAs in gynaecological cancers using more clinical samples and large-scale expression profiling methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. Ca-Cancer J Clin 64:9–29. doi:10.3322/caac.21208

    Article  PubMed  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M et al. (eds) (2013) SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD. [http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013].

  3. Zavesky L, Jancarkova N, Kohoutova M (2011) Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 58:457–468. doi:10.4149/neo_2011_06_457

    Article  CAS  PubMed  Google Scholar 

  4. Devor EJ, Hovey AM, Goodheart MJ et al (2011) microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep 26:995–1002. doi:10.3892/or.2011.1372

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Banno K, Nogami Y, Kisu I et al (2013) Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer. Int J Mol Sci 14(6):12123–12137. doi:10.3390/ijms140612123

    Article  PubMed Central  PubMed  Google Scholar 

  6. Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159. doi:10.1002/emmm.201100209

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Zhao YN, Chen GS, Hong SJ (2014) Circulating MicroRNAs in gynecological malignancies: from detection to prediction. Exp Hematol Oncol 3:14. doi:10.1186/2162-3619-3-14

    Article  PubMed Central  PubMed  Google Scholar 

  8. Weber JA, Baxter DH, Zhang SL et al (2010) The MicroRNA Spectrum in 12 Body Fluids. Clin Chem (Washington, DC, U S) 56:1733–1741. doi:10.1373/clinchem.2010.147405

    Article  CAS  Google Scholar 

  9. Yamada Y, Enokida H, Kojima S et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529. doi:10.1111/j.1349-7006.2010.01816.x

    Article  CAS  PubMed  Google Scholar 

  10. Bryant RJ, Pawlowski T, Catto JWF et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. doi:10.1038/bjc.2011.595

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Mengual L, Loyano JJ, Ingelmo-Torres M et al (2013) Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 133(11):2631–2641. doi:10.1002/ijc.28274

    CAS  PubMed  Google Scholar 

  12. Hanke M, Hoefig K, Merz H et al (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol Semin Orig Invest 28:655–661. doi:10.1016/j.urolonc.2009.01.027

    Article  CAS  Google Scholar 

  13. Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y (2014) Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 5(3):182–191. doi:10.7150/jca.6799

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Wang G, Chan ESY, Kwan BCH et al (2012) Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10(2):106–113. doi:10.1016/j.clgc.2012.01.001

    Article  PubMed  Google Scholar 

  15. Zhao S, Fernald RD (2005) Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 12:1047–1064. doi:10.1089/cmb.2005.12.1047

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Guescini M, Sisti D, Rocchi MBL et al (2008) A new real-time PCR method to overcome significant quantitative inaccuracy due to slight amplification inhibition. BMC Bioinf 9:326. doi:10.1186/1471-2105-9-326

    Article  Google Scholar 

  17. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - excel-based tool using pair-wise correlations. Biotechnol Lett 26:509–515. doi:10.1023/B:BILE.0000019559.84305.47

    Article  CAS  PubMed  Google Scholar 

  18. Andersen CL, Jensen JL, Ørntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250. doi:10.1158/0008-5472.CAN-04-0496

    Article  CAS  PubMed  Google Scholar 

  19. Wyman SK, Parkin RK, Mitchell PS et al (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. Plos One 4:e5311. doi:10.1371/journal.pone.0005311

    Article  PubMed Central  PubMed  Google Scholar 

  20. Resnick KE, Alder H, Hagan JP et al (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112:55–59. doi:10.1016/j.ygyno.2008.08.036

    Article  CAS  PubMed  Google Scholar 

  21. Dahiya N, Sherman-Baust CA, Wang TL et al (2008) MicroRNA expression and identification of putative miRNA targets in ovarian cancer. Plos One 3(6):e2436. doi:10.1371/journal.pone.0002436

    Article  PubMed Central  PubMed  Google Scholar 

  22. Hausler SFM, Keller A, Chandran PA et al (2010) Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 103:693–700. doi:10.1038/sj.bjc.6605833

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Shapira I, Oswald M, Lovecchio J et al (2014) Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer 110:976–983. doi:10.1038/bjc.2013.795

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Laios A, O’Toole S, Flavin R et al (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7:35. doi:10.1186/1476-4598-7-35

    Article  PubMed Central  PubMed  Google Scholar 

  25. Dong P, Kaneuchi M, Watari H et al (2014) MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog 53:349–359. doi:10.1002/mc.21983

    Article  CAS  PubMed  Google Scholar 

  26. Ni X, Xia T, Zhao T et al (2014) Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci 105:18–25. doi:10.1111/cas.12309

    Article  CAS  PubMed  Google Scholar 

  27. Hiroki E, Akahira J, Suzuki F et al (2010) Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101:241–249. doi:10.1111/j.1349-7006.2009.01385.x

    Article  CAS  PubMed  Google Scholar 

  28. Kan CWS, Hahn MA, Gard GB et al (2012) Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12:627. doi:10.1186/1471-2407-12-627

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are very grateful to Petra Soukupová, M.D., Laura Sucharovová, M.D. and Veronika Hanzíková, M.D. (Transfusion Department, General University Hospital Prague) involved in control patients sampling. We also thank Marta Číhalová, M.D. participating in sampling in FN Brno. We thank Jitka Pavlíková (FN Brno), Stanislava Štursová and Martina Vinopalová (Institute of the Care of Mother and Child Prague) ensuring samples collection. We are very grateful to Markéta Tesařová, Ph.D. (Department of Pediatrics and Adolescent Medicine 1. LF UK and VFN) allowing to analyse samples on Agilent 2100 Bioanalyzer. Performing Cy0 analyses by Cy0 team (www.cy0method.org) is greatly acknowledged, namely we thank Renato Panebianco for his kind cooperation. The financial support from the Charles University Prague (project PRVOUK-P27/LF1/1) is also greatly appreciated. Clinical part in FN Brno was supported by Ministry of Health of the Czech Republic – project FNBr 65269705.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Biology and Medical Genetics, the First Faculty of Medicine, Charles University Prague and General University Hospital in Prague, Albertov 4, CZ-128 00, Prague 2, the Czech Republic

    Luděk Záveský, Aleš Hořínek & Milada Kohoutová

  2. Institute of Pathology, University Hospital Brno, Obilní trh 11, CZ-625 00, Brno, the Czech Republic

    Eva Jandáková

  3. Institute for the Care of Mother and Child, Podolské nábřeží 157, CZ-147 00, Prague 4, the Czech Republic

    Radovan Turyna & Jaroslav Feyereisl

  4. Faculty Transfusion Centre, General University Hospital in Prague, U Nemocnice 2, CZ-128 08, Prague 2, the Czech Republic

    Lucie Langmeierová & Daniela Dušková

  5. Department of Obstetrics and Gynaecology, University Hospital Brno, Obilní trh 11, CZ-625 00, Brno, the Czech Republic

    Vít Weinberger & Luboš Minář

  6. Institute of Botany of the ASCR, v. v. i., Academy of Sciences of the Czech Republic, Zámek 1, CZ-252 43, Prague 4, the Czech Republic

    Lenka Záveská Drábková

  7. Institute of Molecular Genetics of the ASCR, v. v. i., Vídeňská 1083, CZ-142 20, Prague 4, the Czech Republic

    Lenka Záveská Drábková

  8. Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Ke Karlovu 2, CZ-121 00, Prague 2, the Czech Republic

    Martina Hůlková

Authors
  1. Luděk Záveský
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Jandáková
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Radovan Turyna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucie Langmeierová
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vít Weinberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lenka Záveská Drábková
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martina Hůlková
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aleš Hořínek
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniela Dušková
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jaroslav Feyereisl
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Luboš Minář
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Milada Kohoutová
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luděk Záveský.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 24 kb)

ESM 2

(DOCX 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Záveský, L., Jandáková, E., Turyna, R. et al. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study. Pathol. Oncol. Res. 21, 1027–1035 (2015). https://doi.org/10.1007/s12253-015-9914-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-015-9914-y

Keywords

Search

Navigation